Vanguard Global Advisers’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Global Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,264	Closed	-$645K	–	3724
2026 Q1	$645K	Buy	+19,264	New	+$755K	﹤0.01%	1916

Vanguard Global Advisers's SLNO Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 19,264 shares — an estimated $645K sold.

Vanguard Global Advisers first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $645K in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vanguard Global Advisers reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 19,264 Soleno Therapeutics shares in Q2 2026, an estimated $645K.
Vanguard Global Advisers first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's Soleno Therapeutics position peaked at $645K in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.